Researchers at the Icahn School of Medicine at Mount Sinai have identified immune system changes that can be detected up to 10 years before inflammatory bowel disease (IBD) develops, offering new ...

BERLIN — An individual’s profile of antibody responses to a range of herpes viruses and encapsulated bacteria such as Streptococcus could predict the onset of inflammatory bowel disease (IBD) up to 10 ...

Researchers from Elpiscience Biopharmaceuticals Inc. hypothesized that dual targeting of the TL1A/DR3 and IL-23 signaling pathways with a single bispecific antibody would exert superior efficacy by ...

Researchers estimate that more than 4.9 million people globally are living with inflammatory bowel disease (IBD) — an umbrella term for two conditions, ulcerative colitis (UC) and Crohn’s disease, ...

Crohn's disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic ...

(RTTNews) - Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotech company focused on innovative antibody therapies for Inflammatory Bowel Disease or IBD and related immune disorders, Monday ...

The co-antibody therapy JNJ-4804 -- a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) -- showed clinically meaningful efficacy exceeding that of either drug alone in patients ...

In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors ...

Teva Pharmaceuticals’TEVA-4.07%decrease; down pointing triangle shares soared and Sanofi’s SAN-0.54%decrease; down pointing triangle stock moved higher following positive results from the latest trial ...

A new study indicates that a combo therapy approach may be better for treating Crohn's and ulcerative colitis. BONNINSTUDIO/Stocksy There is currently no cure for IBD. Current treatments focus on ...